MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
Isabel Bär, PhD candidate at Erasmus MC, shared a proud post on LinkedIn:
”Unraveling the cause of a rare disease by studying an even rarer disease… Who says scientists aren’t creative!
So proud of my amazing colleague Sophie Hordijk, under supervision of Ruben Bierings and Frank Leebeek, for investigating the secretion machinery in a disease affecting only 26 patients worldwide and uncovering insights that bring us closer to solving a major mystery in the most common inherited bleeding disorder globally: Von Willebrand disease.
These findings could help explain why around 20% of Von Willebrand disease patients bleed without carrying mutations in their Von Willebrand factor gene. The identification of MADD as the first causal gene for quantitative Von Willebrand disease is a great example of how rare disease research can unlock answers to broader medical questions.
No wonder that Amazing Erasmus MC picked up on it – truly amazing work, congratulations!
If you want to know why it was necessary to go to 4 different countries (Czech Republic, Germany, Belgium, and the UK) to perform this study, check out the interview.
And if you’re looking for a deeper scientific dive beyond this interview, check the recently published results in Blood!”
To learn more, follow the link.
Read the full article here.
Article: A novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variants
Authors: Sophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N.J. Laan, Georg-Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W.G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben Bierings
Stay updated on the latest scientific advancements in the field of bleeding disorders with Hemostasis Today.
-
Aug 5, 2025, 00:15Heghine Khachatryan Shares Highlights from WFH on PROBE and WBDR Impact
-
Aug 5, 2025, 00:05CHEST 2022 Guidelines: Perioperative Management of Antithrombotic Therapy
-
Aug 4, 2025, 17:06Nathan Connell and John Fanikos Invite You to the Vasculearn Network Podcast
-
Aug 4, 2025, 16:44Honoring Visionary Leadership in Hemophilia Care: A Tribute to Drs. Cesar Garrido and Assad Haffar
-
Aug 4, 2025, 14:54Shreyas Kalantri: Engaging Insights on VTE Management
-
Aug 4, 2025, 17:29MADD: First Causal Gene for Quantitative Von Willebrand Disease Discovered
-
Aug 4, 2025, 16:13Nicolas Gendron on TITAN’s Recent Study: Insights on Managing Pregnancy in Antithrombin Deficiency
-
Aug 4, 2025, 01:59Michael Makris Posts Haemophilia Journal Article Reassessing UK Blood Inquiry
-
Aug 4, 2025, 01:09Manuel Monreal Congratulates Authors Ahead of JTH Publication: VTE-Predict Score Validated in RIETE Cohort
-
Aug 3, 2025, 17:48Nathan Connell: What Is The "Mild Equivalent" For Hemophilia A That Is Achieved While on Emicizumab?
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 4, 2025, 05:20NBCA: Alexis’s DVT Diagnosis Came Without Warning - Learn How She Caught It Early
-
Aug 4, 2025, 00:50NBCA: After Losing Her Daughter to a Blood Clot, Charita Fights to Save Others
-
Aug 3, 2025, 18:10Andrew Agwunobi Congrats Dr. Oladipo Cole and The Whole Team at the Connecticut Bleeding Disorder Center
-
Aug 3, 2025, 12:03Elias Bouchi Presents Werfen EEMEA Talks on Hemostasis: Clot Stories Season 3
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab